🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to health experts.

An International Public Health Issue

Gonorrhoea infections are escalating globally, with estimates suggesting over 82 million infections annually. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options currently available.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The WHO has classified it as a "critical concern". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Gain Authorization

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists believe that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in concurrent days. This medication, which is employed against UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This authorization marks a major breakthrough in the treatment of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

According to results detailed in a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which involves a dual-drug approach. The research included hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the authority to make available and distribute the drug in many low-income and middle-income countries.

Clinicians treating patients have shared hope. Having a easy-to-administer therapy of this kind is hailed as a "critical tool" for gonorrhoea control. This is considered essential to lessen the impact of the illness for people and to halt the transmission of untreatable gonorrhoea globally.